Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2061250056) titled 'An Open-Label, Uncontrolled, Single Arm Clinical Trial of ACP-015 in Children with Achondroplasia Aged 2 to 11 Years' on Sept. 29.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Fujita Mariko
Condition:
Achondroplasia
Intervention:
Navepegritide will be administered subcutaneously once weekly at a dose of 100 microg/kg.
The duration of treatment will be 52 weeks....
Recruitment Status: Recruiting
Phase: 3
Date of First Enrollment: 01/10/2025
Target Sample Size: 12
To know more, visit ...